| Seoul office expands JNPMEDI’s nationwide CRO presence beyond its Songdo headquarters.
| Located in the KCCI building, strengthening proximity to key government and industry networks.
| Established as a new hub for global clinical development and partnership expansion.
| Office design reflects global regulatory focus, with rooms named after MFDS, FDA, EMA, and PMDA.
JNPMEDI has expanded its footprint with a new Seoul office, positioning the AI-driven clinical trial solutions company closer to Korea’s core biopharma and regulatory networks.
The company, headquartered in Songdo—a major life science cluster—said the Seoul office opened this month inside the Korea Chamber of Commerce and Industry (KCCI) building near Seoul Station, a location known as a central conduit between industry and government. JNPMEDI framed the move as a strategic step to strengthen client access and accelerate global partnership development.
Inside, the company has aligned the space with its global orientation: key meeting rooms are named after major regulatory agencies—MFDS, FDA, EMA, and PMDA—reflecting its focus on supporting multinational clinical programs. A dedicated clinical document room equipped with temperature- and humidity-controlled storage and remote monitoring systems has also been established to meet compliance standards.
JNPMEDI said the new office will function as a key node for expanding its clinical development network and reinforcing its presence within Korea’s competitive CRO landscape.
CEO Kwunho Jeong noted that the expansion signals “a step forward in strengthening our response to global clinical development demand,” adding that the company aims to increase service accessibility for domestic and overseas sponsors while advancing its position in international markets.
| Seoul office expands JNPMEDI’s nationwide CRO presence beyond its Songdo headquarters.
| Located in the KCCI building, strengthening proximity to key government and industry networks.
| Established as a new hub for global clinical development and partnership expansion.
| Office design reflects global regulatory focus, with rooms named after MFDS, FDA, EMA, and PMDA.
JNPMEDI has expanded its footprint with a new Seoul office, positioning the AI-driven clinical trial solutions company closer to Korea’s core biopharma and regulatory networks.
The company, headquartered in Songdo—a major life science cluster—said the Seoul office opened this month inside the Korea Chamber of Commerce and Industry (KCCI) building near Seoul Station, a location known as a central conduit between industry and government. JNPMEDI framed the move as a strategic step to strengthen client access and accelerate global partnership development.
Inside, the company has aligned the space with its global orientation: key meeting rooms are named after major regulatory agencies—MFDS, FDA, EMA, and PMDA—reflecting its focus on supporting multinational clinical programs. A dedicated clinical document room equipped with temperature- and humidity-controlled storage and remote monitoring systems has also been established to meet compliance standards.
JNPMEDI said the new office will function as a key node for expanding its clinical development network and reinforcing its presence within Korea’s competitive CRO landscape.
CEO Kwunho Jeong noted that the expansion signals “a step forward in strengthening our response to global clinical development demand,” adding that the company aims to increase service accessibility for domestic and overseas sponsors while advancing its position in international markets.